This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ESB865. CME/NCPD/AAPA/IPCE credit will be available until February 23, 2026.

Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy With GPRC5D-Targeting Options

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.

Disclosure information is available at the beginning of the video presentation.